article_snippet: Ibrutinib is one of only a handful of new medicines to be made available via the Cancer Drugs Fund after two trials in 28 British hospitals showed it to be extremely effective in treating both mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL).
article_snippet: For the time being, a course of ibrutinib – which costs up to £74,000 a year – will be prescribed only to patients whose disease does not respond to chemotherapy, or those who have relapsed following chemotherapy.
article_snippet: Jonathan Pearce, chief executive of the Lymphoma Association, also backs the drug.
article_snippet: Jonathan Pearce, chief executive of the Lymphoma Association says: ‘The new class of targeted drug therapies that pharmaceutical companies are currently developing, like ibrutinib, offer hope to many people with lymphoma – both in relation to the efficacy of the treatments and how well tolerated many people with lymphoma are in terms of side effects.
highlights_snippet: Ibrutinib to to be made available via Cancer Drugs Fund after two trials .
  
highlights_snippet: Trials, in 28 British hospitals, showed  it to be extremely effective in treating mantle cell lymphoma and chronic lymphocytic leukaemia .
  
highlights_snippet: For now, ibrutinib (which costs up to £74,000 a year) will be prescribed only to patients whose disease doesn't respond to Chemotherapy .